GLP-1 RA Cases - On-Demand Webcast - Expert Guidance on GLP-1 RA in T2D - Internal Medicine

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of diabetes drugs in patients with high CV risk and/or renal disease
Consider the key clinical evidence from CV outcomes trials with GLP-1 RAs in management decisions for patients with T2D
Differentiate the pharmacokinetic/pharmacodynamic characteristics and side effect profiles of injection and oral GLP-1 RA products to optimize their use according to patient requirements and preferences

Information on this Educational Activity

Faculty

Vanita R. Aroda, MD

Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Faculty
Harvard Medical School
Boston, Massachusetts

Vanita Aroda, MD, has disclosed that she has received consultant fees from Applied Therapeutics, Duke, Pfizer, Novo Nordisk, and Sanofi; funds for research support from Applied Therapeutics/Medpace, Lilly, Novo Nordisk, Premier/Fractyl, Sanofi/Medpace; and that her spouse is an employee at Janssen and Merck.

Arthi Thirumalai, MBBS

Assistant Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

Arthi Thirumalai, MBBS, has disclosed that she has received funds for research support from Novo Nordisk.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Target Audience

This program is intended for endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, and other advanced practice professionals who care for patients with T2D.

Goal

The goal of this activity is to improve the competence and performance of learners in leveraging the glycemic and extraglycemic properties of GLP-1 RA therapies to lower A1C, reduce comorbidity risks, and improve patient adherence and self-care in the management of T2D.

Physician Continuing Medical Education

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Education

In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Expert Guidance on GLP-1 Receptor Agonists in Type 2 Diabetes: A Case-Based Approach CME MOC CE